KAPLAN GILLA 4

What Happened Gilla Kaplan, a director of Avalo Therapeutics, was granted a derivative award covering 20,100 shares on 2026-06-02. The grant is reported at $0.00 (no cash paid at grant). The instrument is a stock option-style award that vests 100% on the first anniversary of the grant date, subject to continued service.

Key Details

• Transaction date: 2026-06-02; Form 4 filed: 2026-06-04 (timely filing).
• Transaction type/code: Award/Grant (A); reported as a derivative instrument.
• Shares/units granted: 20,100; reported acquisition price: $0.00.
• Vesting: 100% vests one year after grant (footnote).
• Shares owned after transaction: Not specified in the provided filing excerpt.
• No exercise price, sale, or tax-withholding transaction is reported in this entry.

Context This is a compensation-related equity grant to a board member (common for directors) rather than an open-market purchase or sale. Because it is a time-vesting option award (not exercised or sold), it does not represent an immediate cash investment by the insider; investors typically view grants as routine compensation rather than a direct bullish or bearish signal.